EAST WINDSOR, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Novitium Pharma LLC today announced that it has received U.S. Food and Drug Administration approval on its Abbreviated New Drug Application (“ANDA”) for Prazosin Hydrochloride Capsules USP 1 mg, 2 mg, and 5 mg, and has immediately initiated commercialization activities. Prazosin Hydrochloride USP is a therapeutic equivalent to the reference listed drug Minipress® of Pfizer Inc. For the 12 months ended June 2018, total U.S. sales of Prazosin Capsules USP 1 mg, 2 mg, and 5 mg was approximately $65 million according to IQVIA.
About Novitium Pharma
Novitium is a U.S. based pharmaceutical company that specializes in development, manufacturing, and distribution of niche generic pharmaceutical products. The company, founded in 2016, has since established a growing commercial product portfolio and developed a pipeline of over 20 ANDAs filed with the FDA, spanning a diverse range of dosage forms and therapeutic categories. Novitium continues to invest in producing affordable, high-quality medication to fulfill the needs of pharmacists, patients, and communities alike.
For more information about Novitium Pharma please visit www.novitiumpharma.com.